ArticleNaunyn-Schmiedeberg's archives of pharmacology2018

Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice.

Atsuo Tahara et al.PubMed ↗Publisher ↗

No numbers read from the abstract.